SI2233135T1 - Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov - Google Patents

Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov

Info

Publication number
SI2233135T1
SI2233135T1 SI200830749T SI200830749T SI2233135T1 SI 2233135 T1 SI2233135 T1 SI 2233135T1 SI 200830749 T SI200830749 T SI 200830749T SI 200830749 T SI200830749 T SI 200830749T SI 2233135 T1 SI2233135 T1 SI 2233135T1
Authority
SI
Slovenia
Prior art keywords
hemangiomas
medicament
manufacture
treatment
beta blocker
Prior art date
Application number
SI200830749T
Other languages
English (en)
Inventor
Christine Leaute-Labreze
De La Roche Eric Dumas
Alain Taieb
Jean-Benoit Thambo
Original Assignee
Univ Bordeaux Segalen
Ct Hospitalier Universitaire De Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2233135(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Bordeaux Segalen, Ct Hospitalier Universitaire De Bordeaux filed Critical Univ Bordeaux Segalen
Publication of SI2233135T1 publication Critical patent/SI2233135T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
SI200830749T 2007-10-19 2008-10-16 Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov SI2233135T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291273A EP2050441A1 (en) 2007-10-19 2007-10-19 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US98950707P 2007-11-21 2007-11-21
EP09015563.1A EP2233135B8 (en) 2007-10-19 2008-10-16 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Publications (1)

Publication Number Publication Date
SI2233135T1 true SI2233135T1 (sl) 2012-10-30

Family

ID=39156667

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200830749T SI2233135T1 (sl) 2007-10-19 2008-10-16 Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov
SI200830362T SI2187878T1 (sl) 2007-10-19 2008-10-16 Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200830362T SI2187878T1 (sl) 2007-10-19 2008-10-16 Uporaba beta-blokatorja za proizvodnjo zdravila za zdravljenje hemangiomov

Country Status (31)

Country Link
US (2) US8338489B2 (sl)
EP (3) EP2050441A1 (sl)
JP (1) JP5552700B2 (sl)
KR (2) KR20150110827A (sl)
CN (2) CN102006864B (sl)
AR (1) AR068927A1 (sl)
AT (1) ATE512661T1 (sl)
AU (1) AU2008313405B2 (sl)
BR (1) BRPI0816536A2 (sl)
CA (1) CA2701953C (sl)
CL (1) CL2008003083A1 (sl)
CO (1) CO6270209A2 (sl)
CY (1) CY1112604T1 (sl)
DE (1) DE08838691T1 (sl)
DK (2) DK2233135T3 (sl)
ES (2) ES2390534T3 (sl)
HK (1) HK1148940A1 (sl)
HR (2) HRP20110659T1 (sl)
IL (1) IL205129A (sl)
MA (1) MA31843B1 (sl)
MX (1) MX2010004295A (sl)
MY (1) MY156750A (sl)
NZ (1) NZ584307A (sl)
PA (1) PA8799401A1 (sl)
PL (2) PL2233135T3 (sl)
PT (2) PT2233135E (sl)
RU (1) RU2471500C2 (sl)
SI (2) SI2233135T1 (sl)
TN (1) TN2010000170A1 (sl)
TW (1) TWI531365B (sl)
WO (1) WO2009050567A2 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
WO2010118340A1 (en) 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20140170112A1 (en) * 2011-03-12 2014-06-19 Vicus Therapeutics, Llc Compositions for ameliorating systemic inflammation and methods for making and using them
CN102579412A (zh) * 2012-02-16 2012-07-18 山东省立医院 一种治疗婴幼儿血管瘤的外用药物及其制备方法
CN103536607A (zh) * 2012-07-10 2014-01-29 邵金辉 土霉素，普罗帕酮和安乃近的抗肿瘤作用
CN103054793B (zh) * 2013-01-05 2015-01-21 广州军区广州总医院 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN104274390B (zh) * 2014-09-04 2017-06-13 郑家伟 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用
RU2584082C1 (ru) * 2015-01-21 2016-05-20 Ильдар Наилевич Нурмеев Способ лечения гемангиом
CN105434337B (zh) * 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途
CN105106105A (zh) * 2015-08-14 2015-12-02 天津市聚星康华医药科技有限公司 噻吗洛尔外用制剂治疗婴幼儿血管瘤的应用及其制备方法
US20170360829A1 (en) * 2016-01-27 2017-12-21 Gillies Mcindoe Research Institute Treatment of vascular anomalies
RU2617516C1 (ru) * 2016-03-24 2017-04-25 Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт неотложной детской хирургии и травматологии Департамента здравоохранения города Москвы Способ лечения младенческих гемангиом
CN106474061B (zh) * 2016-12-08 2019-01-22 黑龙江童医生儿童生物制药有限公司 一种盐酸普萘洛尔口服乳剂及其制备方法
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
CA3072389A1 (en) * 2017-08-07 2019-02-14 Consejo Superior De Investigaciones Cientificas Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
CN110314154A (zh) * 2018-03-28 2019-10-11 武汉恒信源药业有限公司 左旋普萘洛尔在制备治疗血管病变药物中的应用
US20210346319A1 (en) * 2018-10-04 2021-11-11 Emory University Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto
RU2701213C1 (ru) * 2018-12-27 2019-09-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения инфантильных гемангиом
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
US20220218716A1 (en) * 2019-05-24 2022-07-14 Pediatric Derm Developement Llc Treatment of infantile hemangioma
CN111773226A (zh) * 2019-06-26 2020-10-16 首都医科大学附属北京儿童医院 噻吗洛尔或其盐在制备预防和/或治疗丛状血管瘤的药物中的用途
US20230090708A1 (en) * 2020-01-29 2023-03-23 Massey Ventures Limited Methods and compositions for the treatment of hemangioma
US20230248671A1 (en) * 2020-07-10 2023-08-10 Chang Gung Memorial Hospital, Linkou Use of beta-1 adrenergic receptor antagonist for preparing compositions for reducing epithelial cell damage induced by epidermal growth factor receptor inhibitors and inhibiting cancer cells
CN116472036A (zh) * 2020-09-30 2023-07-21 日产化学株式会社 包含水溶性β阻断剂及卵磷脂的复合体
CN113274348A (zh) * 2021-06-11 2021-08-20 四川大学华西医院 用于治疗婴幼儿血管瘤的阿替洛尔凝胶、制备方法及应用
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (sl) * 1962-12-11
US3466325A (en) * 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
GB1253709A (en) 1968-05-22 1971-11-17 Frosst & Co Charles E Thiadiazole derivatives
US3657237A (en) * 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
SE354851B (sl) * 1970-02-18 1973-03-26 Haessle Ab
AT334385B (de) * 1973-12-20 1976-01-10 Chemie Linz Ag Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
DK1155689T3 (da) * 1993-07-19 2006-11-20 Angiotech Pharm Inc Antiangiogene stents og fremgangsmåder til fremstilling heraf
NZ332645A (en) * 1996-05-01 2000-07-28 Lilly Co Eli use of a bis-indolylmaleimide derivative for treating VEGF related diseases
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
EP1389201A1 (de) * 2001-05-08 2004-02-18 Schering Aktiengesellschaft N-oxidanthranylamid-derivate und deren verwendung als arzneimittel
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
EP1781331A1 (en) * 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Also Published As

Publication number Publication date
ATE512661T1 (de) 2011-07-15
HRP20120765T1 (hr) 2012-10-31
EP2187878B1 (en) 2011-06-15
TN2010000170A1 (en) 2011-11-11
EP2233135A1 (en) 2010-09-29
KR20150110827A (ko) 2015-10-02
CN103169971A (zh) 2013-06-26
MX2010004295A (es) 2010-08-02
PT2187878E (pt) 2011-09-07
EP2233135B8 (en) 2013-07-10
US20130072551A1 (en) 2013-03-21
WO2009050567A2 (en) 2009-04-23
TWI531365B (zh) 2016-05-01
NZ584307A (en) 2012-03-30
US20100273889A1 (en) 2010-10-28
ES2368299T3 (es) 2011-11-16
RU2471500C2 (ru) 2013-01-10
DK2187878T3 (da) 2011-09-19
MA31843B1 (fr) 2010-11-01
AU2008313405A1 (en) 2009-04-23
PT2233135E (pt) 2012-09-06
PL2233135T3 (pl) 2012-11-30
BRPI0816536A2 (pt) 2017-06-06
JP2011500661A (ja) 2011-01-06
AR068927A1 (es) 2009-12-16
CO6270209A2 (es) 2011-04-20
RU2010112816A (ru) 2011-11-27
IL205129A0 (en) 2010-11-30
CN102006864A (zh) 2011-04-06
EP2233135B1 (en) 2012-06-27
PL2187878T3 (pl) 2012-01-31
SI2187878T1 (sl) 2011-10-28
CA2701953A1 (en) 2009-04-23
ES2390534T3 (es) 2012-11-13
CY1112604T1 (el) 2016-02-10
HRP20110659T1 (hr) 2011-10-31
IL205129A (en) 2015-05-31
EP2050441A1 (en) 2009-04-22
MY156750A (en) 2016-03-31
JP5552700B2 (ja) 2014-07-16
HK1148940A1 (en) 2011-09-23
CN102006864B (zh) 2013-01-16
KR101562627B1 (ko) 2015-10-22
CL2008003083A1 (es) 2009-03-06
WO2009050567A3 (en) 2009-06-18
EP2187878A2 (en) 2010-05-26
KR20100087012A (ko) 2010-08-02
DK2233135T3 (da) 2012-10-01
US8338489B2 (en) 2012-12-25
AU2008313405B2 (en) 2013-12-19
TW200932207A (en) 2009-08-01
US9173858B2 (en) 2015-11-03
DE08838691T1 (de) 2010-08-26
PA8799401A1 (es) 2009-05-15
CA2701953C (en) 2015-05-19

Similar Documents

Publication Publication Date Title
HK1148940A1 (en) Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
HK1224200A1 (zh) 用於治療胰腺癌的藥物
ZA201003550B (en) Patient interface assembly for respiratory therapy
IL202014A0 (en) A synergistic pharmaceutical combination for the treatment of cancer
IL236360A0 (en) Inhalable medicine
IL203051A (en) Use of alpha-ketoglutarate for drug preparation
EP2131780A4 (en) NEEDLE UNIT FOR ENDODONTIC TREATMENT
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
IL199223A0 (en) Alpha b-crystallin as a therapy for inflammation
EP2276505A4 (en) USE OF MATERIAL FOR MANUFACTURING A MEDICAMENT FOR TREATING A BANAL COLD
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
HK1134911A1 (en) Medicament for the treatment of endometriosis
EP2135604A4 (en) PREPARATION OF INFUSION FOR PATIENT SUFFERING FROM CANCER
GB0702537D0 (en) Treatment for excessive adiposity
HK1138189A1 (en) Use of a compound in the manufacture of a medicament for the treatment of leukaemia
HK1140530A1 (en) Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0717450D0 (en) Medicament
GB0711139D0 (en) New medicine use
GB2445733B (en) Medical syringe
GB0701813D0 (en) Respiratory medicament applicator
GB0700886D0 (en) Medical treatment
GB0716122D0 (en) New medical use
PL382419A1 (pl) Antybakteryjny opatrunek medyczny
AU315554S (en) Patient medical binder